We can’t show the full text here under this license. Use the link below to read it at the source.
Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?
Balancing the risks of GLP-1 treatment in older adults: Is muscle loss with obesity a concern?
AI simplified
Abstract
GLP-1 receptor agonists may lead to 15-25% weight loss over 12-24 months but raise concerns about muscle mass loss.
- Cessation of GLP-1 receptor agonist treatment often results in significant weight regain.
- Up to two-thirds of users may discontinue treatment within a year due to high costs and side effects.
- Sarcopenic obesity, characterized by high body fat and low muscle mass, is prevalent in 10-20% of older adults.
- Weight cycling from repeated treatment cessation could worsen fat mass gain while decreasing muscle mass.
- There is a need for awareness and preventive strategies regarding the risks of sarcopenic obesity in older adults using GLP-1 receptor agonists.
AI simplified